About the EXPEDITION Study

What is the purpose of the EXPEDITION Study?
This research study is designed to find out if the investigational medication, called solanezumab*, is safe and effective in slowing the impact of Alzheimer’s disease on memory and ability to perform daily activities compared to placebo. A placebo is a substance that has a similar appearance to the study medication but contains no medication.

* Adopted USAN, suggested INN

What is the investigational medication?
The investigational medication being studied is known as solanezumab. It has not been approved by any government agency for sale as a treatment for any condition. The investigational medication is believed to remove a certain protein in the brain that is thought to cause the plaques and tangles that are associated with Alzheimer’s disease. By removing this protein, researchers think that solanezumab has the potential to slow the impact of Alzheimer’s disease on memory and ability to perform daily activities.

Half of study participants will receive a placebo; the other half will receive the study drug. A computer will randomly decide which study treatment participants will receive. Neither the study participants, their study partners, nor the study doctor will know which study treatment participants are receiving.

How will the study medication be administered?
The investigational medication will be administered in the form of an intravenous (IV) infusion. The entire procedure will take about 30 minutes each time participants visit the study site. Most study visits involve other procedures and questionnaires as well. The study doctor will be able to tell you more about this.

What happens during the EXPEDITION Study?
As part of the EXPEDITION Study, qualified participants will be asked to undergo a thorough physical exam and complete several questionnaires to confirm eligibility. If eligible, study participants will:

Receive the study medication once every 4 weeks, answer questions about their health, and undergo other tests during the study visits.
Attend up to 23 visits over approximately 19 months
Be asked to comply with all study procedures and requirements.

Caregivers or study partners would need to:

Spend at least 10 hours per week with the study participant.
Come to all study visits and answer questions about the study participant’s health.
Communicate with the study team and be willing to comply with all protocol requirements.

Taking part in a clinical study is voluntary. Participants can choose to end participation in this study at any time, for any reason.

Will we have to pay for the study medication?
No. The investigational medication, study-related office visits, and laboratory tests are provided to qualified participants at no cost.

Find out if you pre-qualify to participate


	BEGIN QUESTIONNAIRE